The resistance mechanisms of EGFR TKIs mainly include T790M mutation, cell-mesenchymal epithelial transition factor (C-MET) and human epidermal growth factor receptor 2 (HER2) gene amplification, kirsten rat sarcoma viral oncogene (KRAS) gene mutation, vrafmurine sarcoma viral oncegene homolog B (BRAF) gene mutation, and SCLC transformation (5–9). Here, ERBB2 is linked to small cell lung carcinoma.